CMS Oversight of Manufacturer-Reported Average Sales Price Data
CMS's review of manufacturer-reported average sales price (ASP) data is a vital component of its oversight of Medicare reimbursement for Part B drugs. CMS uses ASPs reported by manufacturers to calculate Medicare Part B drug reimbursement amounts paid to health care providers. Congress has directed the HHS Office of Inspector General to submit a report to Congress-no later than January 1, 2023-that includes an assessment of the accuracy of ASP data submitted by prescription drug manufacturers and recommendations for how to improve the accuracy of that data. This report will identify any potential gaps in CMS oversight and potentially make recommendations to improve the accuracy of: (1) ASP data reporting and (2) Medicare payment amounts calculated from that data.
|Announced or Revised||Agency||Title||Component||Report Number(s)||Expected Issue Date (FY)|
|November 2021||Centers for Medicare and Medicaid Services||CMS Oversight of Manufacturer-Reported Average Sales Price Data||Office of Evaluation and Inspections||OEI-03-21-00390||2023|